

## Public Workshop on COVID-19 Lessons Learned: Clinical Evaluation of Therapeutics

September 28, 2021 1-5:30pm Eastern

## Agenda

1pm	Welcome and Introduction	
Kevin Bugin, PhD, Acting Deputy Director of Operations, Office of New Drugs, Center for Drug Evaluation and Research, FDA; Former Therapeutics Chief of Staff, Federal COVID-19 Response or Countermeasures Acceleration Groups (formerly known as Operation Warp Speed) Susan C. Winckler, RPh, Esq., CEO, Reagan-Udall Foundation for the FDA		
1:15pm	Opening Plenary	
Janet Woodcock, MD, Acting Commissioner of Food and Drugs, FDA Francis S. Collins, MD, PhD, Director, National Institutes of Health		
1:45pm	Research, Scoping, & Prioritization Panel	
Moderated by Stacey Adam, PhD, Associate Vice President, Research Partnerships, Foundation for the National Institutes of Health Michael Santos, PhD, Vice President, Science, Foundation for the National Institutes of Health		
<ul> <li>Panelists:</li> <li>Janet Woodcock, MD, Acting Commissioner of Food and Drugs, FDA</li> <li>Phyllis Arthur, MBA, Vice President, Infectious Diseases &amp; Diagnostics Policy, BIO</li> <li>Elliott Levy, MD, COVID R&amp;D Consortium</li> <li>Sarah Read, MD, Deputy Director, Division of AIDS, National Institute of Allergy and Infectious Diseases and Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Therapeutics-Clinical Work Group Co-Chair</li> </ul>		
2:45pm	Infrastructure & Resourcing Panel	
	Moderated by Esther Krofah, Executive Director, FasterCures and Center for Public Health, Milken Institute Kristin Schneeman, Director, FasterCures, Milken Institute	
H M Ti Ja	arbara Bierer, MD, Faculty Director, Multi-Regional Clinical Trials Center of Brigham and Women's ospital and Harvard; Professor of Medicine, Harvard Medical School and Brigham and Women's Hospital lichael Kurilla, MD, PhD, Director, Division of Clinical Innovation, National Center for Advancing ranslational Sciences, National Institutes of Health Imes Mayne, Vice President, Science Advocacy, PhRMA oug Peddicord, PhD, Executive Director, Association of Clinical Research Organizations	
3:45pm	Clinical Trial Execution Panel	
Moderated by Mark McClellan, MD, PhD, Robert J. Margolis Professor of Business, Medicine, and Policy, and founding Director of the Duke-Margolis Center for Health Policy, Duke University Sarah Sheehan, MPA, Managing Associate, Duke Margolis Center for Health Policy		

Panelists:

- Samuel Brown, MD, MS, Attending Physician, Intermountain Medical Center and Assistant Professor of Pulmonary and Critical Care, University of Utah School of Medicine Intermountain
- Janice Chang, Chief Operating Officer, TransCelerate BioPharma Inc.
- Monica Webb Hooper, PhD, Deputy Director, National Institute on Minority Health and Health Disparities
- Kate Zenlea, MPH, CPH, Managing Director, The Global Health Initiative at Henry Ford Health System

4:45pm	Public Comment
Open to those who submitted comments in Docket; time permitting	
5:15pm	Closing Plenary
Kevin Bugin, PhD, Acting Deputy Director of Operations, Office of New Drugs, Center for Drug Evaluation and	
Research, FDA; Former Therapeutics Chief of Staff, Federal COVID-19 Response or Countermeasures Acceleration	
Groups (formerly known as Operation Warp Speed)	